Goeppert B, Frauenschuh L, Zucknick M, et al. Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer. Br J Cancer. 2013;109(10):2665–74. https://doi.org/10.1038/bjc.2013.610.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Oh DY, He AR, Qin S, et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. J Clin Oncol. 2022;40(4):378. https://doi.org/10.1200/JCO.2022.40.4_suppl.378.

Article  Google Scholar 

Ricci AD, Rizzo A, Brandi G. The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora’s box? ESMO Open. 2020;5(5):e001042. https://doi.org/10.1136/esmoopen-2020-001042.

Article  PubMed  PubMed Central  Google Scholar 

Sahin TK, Rizzo A, Aksoy S, et al. Prognostic significance of the Royal Marsden Hospital (RMH) Score in patients with cancer: a systematic review and meta-analysis. Cancers (Basel). 2024;16(10):1835. https://doi.org/10.3390/cancers16101835.

Article  PubMed  CAS  Google Scholar 

Guven DG, Erul E, Kaygusuz Y, et al. Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data. Support Care Cancer. 2023;31(12):624. https://doi.org/10.1007/s00520-023-08083-w.

Article  PubMed  Google Scholar 

Rizzo A, Mollica V, Tateo V, et al. Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study. Cancer Immunol Immunother. 2023;72(6):1381–94. https://doi.org/10.1007/s00262-023-03366-x.

Article  PubMed  PubMed Central  Google Scholar 

Rizzo A, Santoni M, Mollica V, et al. Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study. Expert Opin Drug Metab Toxicol. 2021;17(12):1455–66. https://doi.org/10.1080/17425255.2021.2029405.

Article  PubMed  CAS  Google Scholar 

Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5):671–84. https://doi.org/10.1016/S1470-2045(20)30109-1.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(6):796–807. https://doi.org/10.1016/S1470-2045(20)30157-1.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1–10. https://doi.org/10.1200/JCO.19.02105.

Article  PubMed  CAS  Google Scholar 

Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353–65. https://doi.org/10.1016/S1470-2045(20)30445-9.

Article  PubMed  CAS  Google Scholar 

Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10391):1853–65. https://doi.org/10.1016/S0140-6736(23)00727-4.

Article  PubMed  Google Scholar 

Mody K, Jain P, El-Refai SM, et al. Clinical, genomic, and transcriptomic data profiling of biliary tract cancer reveals subtype-specific immune signatures. JCO Precis Oncol. 2022;6: e2100510. https://doi.org/10.1200/PO.21.00510.

Article  PubMed  PubMed Central  Google Scholar 

Graham RP, Barr Fritcher EG, Pestova E, et al. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum Pathol. 2014;45(8):1630–8. https://doi.org/10.1016/j.humpath.2014.03.014.

Article  PubMed  CAS  Google Scholar 

Büttner R, Longshore JW, López-Ríos F, et al. Implementing TMB measurement in clinical practice: considerations on assay requirements. ESMO Open. 2019;4(1): e000442. https://doi.org/10.1136/esmoopen-2018-000442.

Article  PubMed  PubMed Central  Google Scholar 

Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34. https://doi.org/10.1186/s13073-017-0424-2.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Mody K, Starr J, Saul M, et al. Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers. J Gastrointest Oncol. 2019;10(6):1099–109. https://doi.org/10.21037/jgo.2019.08.08.

Article  PubMed  PubMed Central  Google Scholar 

Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500–1. https://doi.org/10.1056/NEJMc1713444.

Article  PubMed  PubMed Central  Google Scholar 

Valle JW, Lamarca A, Goyal L, et al. New horizons for precision medicine in biliary tract cancers. Cancer Discov. 2017;7(9):943–62. https://doi.org/10.1158/2159-8290.CD-17-0245.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Javle M, Borad MJ, Azad NS, et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2021;22(9):1290–300. https://doi.org/10.1016/S1470-2045(21)00336-3.

Article  PubMed  CAS  Google Scholar 

Savas P, Salgado R, Denkert C, et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. 2016;13(4):228–41. https://doi.org/10.1038/nrclinonc.2015.215.

Article  PubMed  CAS  Google Scholar 

Cimino-Mathews A, Thompson E, Taube JM, et al. PD-L1 (B7–H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Hum Pathol. 2016;47(1):52–63. https://doi.org/10.1016/j.humpath.2015.09.003.

Article  PubMed  CAS  Google Scholar 

Dirix LY, Takacs I, Jerusalem G, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res Treat. 2018;167(3):671–86. https://doi.org/10.1007/s10549-017-4537-5.

Article  PubMed  CAS  Google Scholar 

DeMatteo R, Goldman DA, Lin ST, et al. Clinical outcomes of immune checkpoint inhibitors in HER2-amplified non-small cell lung cancers. J Clin Oncol. 2022;40(16):21098. https://doi.org/10.1200/JCO.2022.40.16_suppl.e21098.

Article  Google Scholar 

Loi S, Giobbie-Hurder A, Gombos A, et al. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial. Lancet Oncol. 2019;20(3):371–82. https://doi.org/10.1016/S1470-2045(18)30812-X.

Article  PubMed  CAS  Google Scholar 

Janjigian YY, Kawazoe A, Yañez P, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600(7890):727–30. https://doi.org/10.1038/s41586-021-04161-3.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhang JW, Yang X, Pan B, et al. Clinical response to adding pyrotinib to pembrolizumab and lenvatinib for HER2-positive advanced intrahepatic cholangiocarcinoma: a case report. World J Surg Oncol. 2023;21(1):108. https://doi.org/10.1186/s12957-023-02983-1.

Article